Novartis is responding to COVID-19 with safety of associates and patients globally our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.
To report an adverse event or any drug related issues concerning Novartis medicianal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event. Fax: 002 02 26031702. E-mail: [email protected]